Autolus Accelerates Commercialization and Expands Product Portfolio
The biopharmaceutical company Autolus has recently reported its fourth quarter 2025 and full year 2025 financial results, showcasing significant advancements in commercialization and product development. During the conference call on March 27, 2026, CEO Dr. Christian Itin highlighted the successful launch of AUCATZYL in the U.S., with $74.3 million in revenue recognized in 2025.
By the end of 2025, Autolus had activated 67 centers and was building on positive physician feedback and reliable product delivery for its second year. The company has reiterated its guidance for 2026, predicting net revenue of $120-$135 million, a shift to positive gross margins in 2026, and an increase in commercial footprint targeting more than 80 activated centers by the end of the year.
Regarding AUCATZYL's performance, Dr. Itin noted that larger volumes would drive down fixed costs and improvements in the operating model would reduce variable costs per batch. This strategic approach is expected to contribute positively to gross margins in 2026.
Additionally, Autolus has achieved regulatory approvals in the EU and U.K., as well as market access in the U.K., allowing for the initiation of the AUCATZYL launch at the beginning of this year. This significant milestone marks a major step forward in expanding its commercial presence and bringing its innovative product to more patients.
Dr. Itin also shared updates on Autolus' Obe-cel, a CAR-T therapy for adult ALL patients. The Real-World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) consortium has collected data from 96 patients treated with Obe-cel within participating institutions. Of these patients, 91 received both infusions, and at the time of analysis, 84 were evaluable for a day 28 assessment for response.
The median follow-up was approximately 137 days from first CAR T-cell infusion, indicating the relatively short duration since the launch year began. Notably, Autolus' real-world outcomes with Obe-cel demonstrated a comparable safety profile to that observed in its prior clinical trial experience in the FELIX study.
The data collected by ROCCA provide valuable insights into the efficacy and safety of Obe-cel in the real-world setting, further supporting the potential of this innovative therapy. Autolus' continued focus on expanding access and understanding the outcomes of their products positions them as a leader in the CAR-T market.
